2016
DOI: 10.1590/1414-431x20155031
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Cysteinyl leukotrienes (CysLTs) have been implicated in seizures and kindling; however, the effect of CysLT receptor antagonists on seizure frequency in kindled animals and changes in CysLT receptor expression after pentylenetetrazol (PTZ)-induced kindling have not been investigated. In this study, we evaluated whether the CysLT1 inverse agonist montelukast, and a classical anticonvulsant, phenobarbital, were able to reduce seizures in PTZ-kindled mice and alter CysLT receptor expression. Montelukast (10 mg/kg… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 38 publications
0
11
0
Order By: Relevance
“…Additionally, CBD decreased the activity and metabolites of 5-LOX in human tumor cells [104]. As some targeted inhibitors of Cys-LT synthesis have been demonstrated to significantly attenuate seizures in treated mice (compared to untreated mice) [105,106] and in epileptic patients [107], this could be an avenue by which CBD exerts an anti-seizure effect, but requires further validation.…”
Section: Cannabinoids Are An Emerging Treatment For Drug-resistantmentioning
confidence: 99%
“…Additionally, CBD decreased the activity and metabolites of 5-LOX in human tumor cells [104]. As some targeted inhibitors of Cys-LT synthesis have been demonstrated to significantly attenuate seizures in treated mice (compared to untreated mice) [105,106] and in epileptic patients [107], this could be an avenue by which CBD exerts an anti-seizure effect, but requires further validation.…”
Section: Cannabinoids Are An Emerging Treatment For Drug-resistantmentioning
confidence: 99%
“… 11 Epidemiologic studies have shown that montelukast reduces the incidence and severity of seizures. 12 , 13 These results indicate that montelukast could be developed into a disease-modifying drug for epilepsy. This review summarizes the current findings on the role of montelukast to control seizures.…”
Section: Introductionmentioning
confidence: 84%
“…It was found that epilepsy is associated with increased levels of inflammatory mediators in the brain, including leukotrienes, which are produced by neurons, glia, and endothelial cells in the BBB. 12 Neutrophils that have breached the BBB can lead to the immediate synthesis of CysLT s. 38 Farias et al demonstrated that cysLT s significantly increase after fluid percussion-induced brain injury, being detected as early as 10 min after injury and continuing to rise over an hour. 39 A pharmacological data provided by Lenz et al also indicated that CysLT 1R antagonism maintains BBB integrity.…”
Section: Epilepsy Pathophysiology and Cysteine Leukotrienesmentioning
confidence: 99%
See 1 more Smart Citation
“…Epilepsy‐related BBB (blood–brain barrier) disruption has been shown to be mediated by Cys‐LT , and modulation of Cys‐LT by montelukast suppresses the development and frequency of seizures in vivo . Clinical evidence also exists highlighting the efficacy of pranlukast in epileptic patients .…”
Section: ‐Lox/cys‐lt/cysltrs In Cns Diseasesmentioning
confidence: 99%